Intelligence Feed event · Capital · 2026-10-07

    Vaxcyte Prices $1B Capital Raise via Common Equity and 1.50% Convertibles

    Question

    Vaxcyte Prices $1B Capital Raise via Common Equity and 1.50% Convertibles

    Direct answer

    Vaxcyte executed a dual-tranche financing transaction raising approximately $1.0 billion in gross proceeds. The offering includes 7.4 million newly issued common shares at $64.00 alongside $500 million in 1.50% convertible senior notes maturing in 2032. The transaction provides balance sheet runway for late-stage conjugate vaccine trials, while establishing immediate supply absorption tests for biotech ECM syndicates.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Vaxcyte Prices $1B Capital Raise via Common Equity and 1.50% Convertibles”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/vaxcyte-prices-1b-capital-raise-via-common-equity-and-1-50-convertibles-fc9d26

    CAPITAL
    Vaxcyte Prices $1B Capital Raise via Common Equity and 1.50% Convertibles
    Vaxcyte executed a dual-tranche financing transaction raising approximately $1.0 billion in gross proceeds. The offering includes 7.4 million newly issued common shares at $64.00 alongside $500 million in 1.50% convertible senior notes maturing in 2032. The transaction provides balance sheet runway for late-stage conjugate vaccine trials, while establishing immediate supply absorption tests for biotech ECM syndicates.
    PCVX
    Impact
    73
    OCT 7
    SIG
    92%
    PCVX
    Vaxcyte Prices $1B Capital Raise via Common Equity and 1.50% Convertibles
    Vaxcyte executed a dual-tranche financing transaction raising approximately $1.0 billion in gross proceeds. The offering includes 7.4 million newly issued common shares at $64.00 alongside $500 million in 1.50% convertible senior notes maturing in 2032. The transaction provides balance sheet runway for late-stage conjugate vaccine trials, while establishing immediate supply absorption tests for biotech ECM syndicates.
    → Primary equity pricing at $64.00 expands share count dilution while delta hedging by convertible arbitrage desks exerts structural selling pressure on PCVX shares.
    Impact
    Vaxcyte executed a dual-tranche financing transaction raising approximately $1.0 billion in gross proceeds. The offering includes 7.4 million newly issued common shares at $64.00 alongside $500 million in 1.50% convertible senior notes maturing in 2032. The transaction provides balance sheet runway for late-stage conjugate vaccine trials, while establishing immediate supply absorption tests for biotech ECM syndicates.
    Affected
    PCVX
    Transmission
    Primary equity pricing at $64.00 expands share count dilution while delta hedging by convertible arbitrage desks exerts structural selling pressure on PCVX shares.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    PCVXequity dilution and convertible arbitrage delta hedging flowMixed1-5dPricing of 7.4M shares at $64.00 and $500M in 1.50% convertible notes

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    PCVXMixed66.96 2026-10-07-2.90%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month